Measuring human brain GABA in vivo - Effects of GABA-transaminase inhibition with vigabatrin

Molecular Neurobiology

Volumn 16, Issue 1, 1998, Pages 97-121

  Petroff, Ognen A C ^a   Rothman, Douglas L ^a  

^a YALE UNIVERSITY   (United States)

Author keywords

1H nuclear magnetic resonance spectroscopy; Antiepileptic drugs; Brain; Epilepsy; GABA transaminase; GABA transporter; Gamma aminobutyric acid; Glutamic acid decarboxylase; Human; Vigabatrin

Indexed keywords

4 AMINOBUTYRATE AMINOTRANSFERASE; 4 AMINOBUTYRIC ACID; ANTICONVULSIVE AGENT; CARBAMAZEPINE; GABACULINE; GABAPENTIN; GLUCOSE; GLUTAMIC ACID; GLUTAMINE; N ACETYLASPARTIC ACID; VIGABATRIN;

4 AMINOBUTYRIC ACID BRAIN LEVEL; AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN METABOLISM; CEREBROSPINAL FLUID LEVEL; COMPLEX PARTIAL SEIZURE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; ENZYME INHIBITION; EPILEPSY; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; KINDLING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OCCIPITAL LOBE; ORAL DRUG ADMINISTRATION; RAT; SYNAPSE VESICLE; TEMPORAL LOBE EPILEPSY;

EID: 0031854966     PISSN: 08937648     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02740605     Document Type: Article

References (126)

1. Ackermann R. F., Engel J., and Phelps M. E. (1986) Identification of seizure-mediating brain structures with the deoxyglucose method: studies of human epilepsy with positron emission tomography, and animal seizure models with contact autoradiography. Adv. Neurol. 44, 921-934.
2. Böhlen P., Huot S., and Palfreyman M. G. (1979) The relationship between GABA concentrations in brain and cerebrospinal fluid. Brain Res. 167, 297-305.
3. 11P NMR spectroscopic study of rat brain in vivo. Magn. Reson. Med. 31, 660-667.
4. 1H spectrum of rat brain by two-dimensional shift correlated and J-resolved NMR spectroscopy. Magn. Reson. Med. 17, 285-304.
5. 1H NMR spectrum of rat brain. Magn. Reson. Med. 30, 38-44.
6. 1H NMR spectra of human brain. Magn. Reson. Med. 32, 294-302.
7. Ben-Menachem E. (1989) Pharmacokinetic effects of vigabatrin on cerebrospinal fluid amino acids in humans. Epilepsin 30(Suppl. 3), S12-S14.
8. Ben-Menachem E., Perrson L. I., and Schlechter P. J. (1988) Effects of single doses of vigabatrin on CSF concentrations of GABA, homocarnosine, homovanillic acid and 5-hydroxyindoleacetic acid in patients with complex partial epilepsy. Epilepsy Res. 2, 96-101.
9. Ben-Menachem E., Persson L. I., and Schlechter P. J. (1989). The effect of different vigabatrin treatment regimens on CSF biochemistry and seizure control in epileptic patients. Br. J. Clin. Pharmacy 27(Suppl. 1), 79S-85S.
10. Ben-Menachem E., Persson Mumford J. P., Haegele K. D., and Huebert N. (1991) The effect of long-term vigabatrin therapy on selected neurotransmitter concentrations in cerebrospinal fluid. J. Child. Neurol. 6(Suppl. 2), 2S11-2S16.
11. Ben-Menachem E., Hamberger A., and Mumford J. (1993) Effect of long-term vigabatrin therapy on GABA and other amino acid concentrations in the central nervous system a case study. Epilepsy Res. 16, 241-243.
12. Bernasconi R., Bittiger H., Schmutz M., Martin P., and Klein M. (1984) Is the estimation of the GABA turnover rate in vivo a tool to differentiate between various types of drugs interfering with the GABA/benzodiazapine/ionophore receptor complex? Neuropharmocology 23, 815-816.
13. Bolton J. B., Rimmer E., Williams J., and Richens A. (1989) The effect of vigabatrin on brain and platelet GABA-transaminase activities. Br. J. Clin. Pharmacy 27(Suppl. 1), 35S-42S.
14. Cendes F., Andermann F., Preul M. C., and Arnold D. L. (1994) Lateralization of temporal lobe epilepsy based on regional metabolic abnormalities in proton magnetic resonance spectroscopic images. Ann. Neurol. 35, 211-216.
15. Cendes F., Stanley J. A., Dubeau F., Andermann F., and Arnold D. L. (1997) Proton magnetic resonance spectroscopic imaging for discrimination of absence and complex partial seizures. Ann. Neurol. 41, 74-81.
16. Chadwick D. W., Marson T., and Kadir Z. (1996) Clinical administration of new antiepileptic drugs: an overview of safety and efficacy. Epilepsia 37(Suppl. 6), S17-S22.
17. 31P NMR study. Neurology 47, 756-760.
18. Connelly A., Jackson G. D., Duncan J. S., King M. D., and Gadian D. G. (1994) Magnetic resonance spectroscopy in temporal lobe epilepsy. Neurology 44, 1411-1417.
19. During M. J. (1994) Dynamic neurochemical alterations in human temporal lobe epilepsy. Clin. Neuroscience 2, 53-63.
20. During M. J. and Spencer D. D. (1993) Extracellular hippocampal glutamate and spontaneous seizure in the conscious human brain. Lancet 341, 1607-1613.
21. During M. J., Ryder K. M., and Spencer D. D. (1995) Hippocampal GABA transporter function in temporal-lobe epilepsy. Nature 376, 174-177.
22. Erlander M. G. and Tobin A. J. (1991) The structural and functional heterogeneity of glutamic acid decarboxylase: a review. Neurochem. Res. 16, 215-226.
23. Fisher R. S. and Kerrigan J. F. (1995) Vigabatrin: toxicity, in Antiepileptic Drugs, 4th ed. (Levy R. H., Mattson R. H., and Meldrum B. S., eds.) Raven, New York, pp. 931-939.
24. Fountain N. B. and Lothman E. W. (1995) Pathophysiology of status epilepticus. J. Clin. Neurophysiol. 12, 326-342.
25. French J. A., Mosier M., Walker S., Sommerville K., Sussman N., and the Vigabatrin Protocol 024 Investigative Cohort. (1996) A double-blind, placebo-controlled study of vigabatrin three g/day in patients with uncontrolled complex partial seizures. Neurology 46, 54-61.
26. Fyske E. M. and Fonnum F. (1988) Uptake of gamma-aminobutyric acid by a synaptic vesicle fraction isolated from rat brain. J. Neurochem. 50, 1237-1242.
27. Gadian D. G. (1995) N-acetylaspartate and epilepsy. Magn. Reson. Imag. 13, 1193-1195.
28. Gallo V., Giovannini C., Suergiu R., and Levi G. (1989) Expression of excitatory amino acid receptors by cerebellar cells of the type-2 astrocyte lineage. J. Neurochem. 52, 1-9.
29. Gallo V., Patrizio M., and Levi G. (1991) GABA release triggered by the activation of neuronlike non-NMDA receptors in cultured type-2 astrocytes is carrier-mediated. Glia 4, 245-255.
30. Garcia P. A., Laxer K. D., van der Grond J., Hugg J. W., Matson G. B., and Weiner M. W. (1994) Phosphorus magnetic resonance spectroscopic imaging in patients with frontal lobe epilepsy. Ann. Neurol. 35, 217-221.
31. Gram L. (1996) Pharmacokinetics of new antiepileptic drugs. Epilepsia 37(Suppl. 6), S12-S16.
32. Gram L., Larsson O. M., Johnsen A., and Schousboe A. (1989) Experimental studies of the influence of vigabatrin on the GABA system. Br. J. Clin. Pharmacy 27(Suppl. 1), 13S-17S.
33. Grove J., Schlechter P. J., Tell G., Koch-Weser J., Sjoerdsma A., Warter J. M., Marescaux C., and Rumbach L. (1981) Increased gamma-aminobutyric acid (GABA), homocarnosine, and beta-alanine in cerebrospinal fluid of patients treated with gamma-vinyl GABA (4-amino-hex-5-enoic acid). Life Sci. 28, 2431-2439.
34. 13C glucose. J. Neurochem. 63, 1377-1385.
35. Halonen T., Lehtinen M., Pitkänen A., Ylinen A., and Riekkinen P. J. (1988) Inhibitory and excitatory amino acids in CSF of patients suffering with complex partial seizures during chronic treatment with gamma-vinyl GABA (vigabatrin). Epilepsy Res. 2, 246-252.
36. Hamberger A., Nystrom B., Larsson S., Silvenius H., and Nordborg C. (1991) Amino acids in the neuronal microenvironment of focal human epileptic lesions. Epilepsy Res. 9, 32-43.
37. Hetherington H., Kuzniecky R., Pan J., Mason G., Morawetz R., Harris C., Faught E., Vaughan T., and Pohost G. (1995) Proton nuclear magnetic resonance spectroscopic imaging of human temporal lobe epilepsy at 4.1 T. Ann. Neurol. 38, 396-404.
38. Honmou O., Kocsis J. D., and Richerson G. B. (1995) Gabapentin potentiates the conductance increase induced by nipecotic acid in CA1 pyramidal neurons in vitro. Epilepsy Res. 20, 193-202.
39. Horton R. W. (1991) GABA dysfunction in animal models of epilepsy, in GABA Mechanisms in Epilepsy (Tunnicliff G. and Raess B. U., eds.), Wiley-Liss, New York, pp. 121-147.
40. 31P magnetic resonance spectroscopic imaging. Neurology 42, 2011-2018.
41. Hugg J. W., Laxer K. D., Matson G. B., Maudsley A. A., and Weiner M. W. (1993) Neuron loss localizes human temporal lobe epilepsy by in vivo proton magnetic resonance spectroscopic imaging. Ann. Neurol. 34, 788-794.
42. 1H magnetic resonance spectroscopic imaging. Ann. Neurol. 40, 236-239.
43. Jackson G. D., Connelly A., Cross J. H., Gordon I., and Gadian D. G. (1994) Functional magnetic resonance imaging of focal seizures. Neurology 44, 850-856.
44. Jung M. J., Lippert B., Metcalf B. W., Böhlen P., and Schlechter P. J. (1977) Gamma-vinyl-GABA (4-amino-hex-5-enoic acid), a new selective irreversible inhibitor of GABA-T: effects on brain metabolism in mice. J. Neurochem. 29, 797-802.
45. Jung M. J. and Palfreyman M. G. (1995) Vigabatrin: mechanisms of action, in Antiepileptic Drugs, 4th ed. (Levy R. H., Mattson R. H., and Meldrum B. S., eds.) Raven, New York, pp. 903-913.
46. Kälviäinen R., Halonen T., Pitkanen A., and Reikkinen P. J. (1993) Amino acid levels in the cerebrospinal fluid of newly diagnosed epileptic patients: effect of vigabatrin and carbamazepine monotherapies. J. Neurochem. 60, 1244-1250.
47. Kälviäinen R., Merbaala E., Sivenius J., and Reikkinen P. J. (1995) Vigabatrin clinical use, in Antiepileptic Drugs, 4th ed. (Levy R. H., Mattson R. H., and Meldrum B. S., eds.) Raven, New York, pp. 925-930.
48. A receptor subunit mRNA concentrations following chronic lorazepam administration. Br. J. Pharmacol. 103, 1285-1287.
49. Kaura S., Bradford H. F., Young A. M. J., Croucher M. J., and Hughes P. D. (1995) Effect of amygdaloid kindling on the content and release of amino acids from the amygdaloid complex: in vivo and in vitro studies. J. Neurochem. 65, 1240-1249.
50. Kocsis J. D. and Honmou O. (1994) Gabapentin increases GABA-induced depolarization in rat neonatal optic nerve. Neurosci. Lett. 169, 181-184.
51. Kocsis J. D. and Mattson R. H. (1996) GABA levels in the brain: a target for new antiepileptic drugs. Neuroscientist 6, 326-334.
52. Kuzniecky R. I. and Jackson G. D. (1995) Magnetic Resonance in Epilepsy. Raven, New York.
53. 31P nuclear magnetic resonance spectroscopy of human temporal lobe epilepsy. Neurology 42, 1586-1590.
54. 31P magnetic resonance spectroscopy of epilepsy, in Neuroimaging in Epilepsy ( Cascino G. D. and Jack C. R., eds.) Butterworth-Heinemann, Boston, pp. 145-150.
55. 13C]d-glucose metabolism in cultured astrocytes and neurons using nuclear magnetic resonance spectroscopy. Dev. Neurosci. 15, 282-288.
56. Levi G. and Gallo V. (1995) Release of neuroactive amino acids from glia, in Neuroglia (Kettenmann H. and Ransom B. R., eds.) Oxford University Press, New York, pp. 815-826.
57. Lloyd K. G., Bossi L., Morselli P. L., Munari C., Rougier M., and Loiseau H. (1986) Altered GABA-mediated synaptic transmission in human epilepsy. Adv. Neurol. 44, 1033-1044.
58. Lortie A., Chiron C., Mumford J., and Dulac O. (1993) The potential for increasing seizure frequency, relapse, and appearance of new seizure types with vigabatrin. Neurology 43, S24-S27.
59. Löscher W. and Frey H. H. (1987) One to three day dose intervals during subchronic treatment of epileptic gerbils with gamma-vinyl GABA: anticonvulsant efficacy and alterations in regional brain GABA levels. Eur. J. Pharmacol. 143, 335-342.
60. Löscher W. and Schmidt D. (1994) Strategies in antiepileptic drug development: is rational drug design superior to random screening and structural variation? Epilepsy Res. 17, 95-134.
61. Löscher W., Jäckel R., and Müller F. (1989) Anticonvulsant and proconvulsant effects of inhibitors of GABA degradation in the amygdala-kindling model. Eur. J. Pharmacol. 163, 1-14.
62. 18F Fluorodeoxyglucose positron emission tomography. Magn. Reson. Med. 37, 18-23.
63. Macdonald R. L. and Meldrum B. S. (1995) Principles of antiepileptic drug action, in Antiepileptic Drugs, 4th ed. (Levy R. H., Mattson R. H., and Meldrum B. S., eds.) Raven, New York, pp. 61-77.
64. Maloteaux J. M, Octave K. N., Gossuin A., Laterre C., and Trouet A. (1987) GABA induces down-regulation in the benzodiazepine-GABA receptor complex in rat cultured neurons. Eur. J. Pharmacol. 144, 173-183.
65. Manor D., Rothman D. L., Mason G. F., Hyder F., Petroff O. A. C., and Behar K. L. (1996) The rate of turnover of cortical GABA from [1-13C] glucose is reduced in rats treated with the GABA-transaminase inhibitor vigabatrin (gamma-vinyl GABA). Neurochem. Res. 21, 1037-1047.
66. Martin D. L. (1987) Regulatory properties of brain glutamate decarboxylase. Cell Mol. Neurobiol. 7, 237-253.
67. Martin D. L. (1992) Synthesis and release of neuroactive substances by glial cells. Glia 5, 81-94.
68. Martin D. L. (1995) The role of glia in the inactivation of neurotransmitters, in Neuroglia (Kettenmann H. and Ransom B. R., eds.) Oxford University Press, New York, pp. 732-745.
69. Martin D. L. and Rimvall K. (1993) Regulation of gamma-aminobutyric acid synthesis in the brain. J. Neurochem. 60, 395-407.
70. Mason G. F., Gruetter R., Rothman D. L., Behar K. L., Shulman R. G., and Novotny E. J. (1995) Simultaneous determination of the rates of the TCA cycle, glucose utilization, alpha-ketoglutarate/glutamate exchange, and glutamine synthesis in human brain by NMR. J. Cereb. Blood Flow Metab. 18, 12-25.
71. Matthews P. M., Andermann F., and Arnold D. L. (1990) A proton magnetic resonance spectroscopic study of focal epilepsy in humans. Neurology 40, 985-989.
72. 3 subunit mRNAs as well as polypeptide expression in primary cultured cerebral cortical neurons. Brain Res. Mol. Brain Res. 24, 159-165.
73. Neal M. J., Cunningham J. R., Shah M. A., and Yazulla S. (1989) Immunocytochemical evidence that vigabatrin in rats causes GABA accumulation in glial cells of the retina. Neurosci. Lett. 98, 29-32.
74. Neal M. J. and Shah M. A. (1990) Development of tolerance to the effects of vigabatrin (gamma-vinyl-GABA) on GABA release from the rat cerebral cortex, spinal cord and retina. Br. J. Pharmacol. 100, 324-328.
75. Ottersen O. P., Zhang N., and Walberg F. (1992) Metabolic compartmentation of glutamate and glutamine: morphological evidence obtained by quantitative immunocytochemistry in rat cerebellum. Neuroscience 46, 519-534.
76. 1H magnetic resonance spectroscopy of extracts of human epileptic neocortex and hippocampus. Neurology 43, 589-594.
77. Peng L., Hertz L., Huang R., Sonnewald U., Petersen S. B., Wetergaard N., Larsson O., and Schousboe A. (1993) Utilization of glutamine and TCA cycle constituents as precursors for transmitter glutamate and GABA. Dev. Neurosci. 15, 367-377.
78. Penry J. K., Wilder B. J., and Sachdeo R. C. (1993) Multicenter dose-response study of vigabatrin in adults with focal (partial) epilepsy (abstract). Epilepsia 34(Suppl. 6), 67.
79. Perry T. (1982) Cerebral amino acid pools, in Handbook of Neurochemistry, 2nd ed., vol. 1, (Lajtha A., ed.), Plenum Press, New York, pp. 151-180.
80. Perry T. L., Hansen S., and Gandham S. S. (1981) Postmortem changes of amino compounds in human and rat brain. J. Neurochem. 36, 406-412.
81. Petroff O. A. C., Behar K. L., and Rothman D. L. (1997) Measuring brain GABA in patients with complex partial seizures, in Jasper's Basic Mechanisms of the Epilepsies (Delgado-Escueda A. V., Wilson W., Olsen R. W., and Porter R. J., ed.) Lippincott-Raven, Philadelphia (in press).
82. Petroff O. A. C., Rothman D. L., Behar K. L., Lamoureux D., and Mattson R. H. (1996a) The effect of gabapentin on brain gamma-aminobutyric acid in patients with epilepsy. Ann. Neurol. 39, 95-99.
83. Petroff O. A. C., Rothman D. L., Behar K. L., and Mattson R. H. (1996b) Human brain GABA levels rise following initiation of vigabatrin therapy, but fail to rise further with increasing dose. Neurology 46, 1459-1463.
84. Petroff O. A. C., Rothman D. L., Behar K. L., and Mattson R. H. (1996c) Low brain GABA level is associated with poor seizure control. Ann. Neurol. 40, 908-911.
85. Petroff O. A. C., Rothman D. L., Behar K. L., Collins T. L., and Mattson R. H. (1996d) Human brain GABA levels rise rapidly following initiation of vigabatrin therapy. Neurology 47, 1567-1571.
86. Petroff O. A. C, Rothman D. L., Behar K. L., and Mattson R. H. (1996e) Human brain gamma-aminobutyric acid (GABA) levels and seizure control following initiation of vigabatrin therapy. J. Neurochem. 67, 2399-2404.
87. 1H spectroscopic measurements of GABA, glutamate, and glutamine in human brain. Epilepsia 36, 457-464.
88. Petroff O. A. C., Pleban L. A., and Spencer D. D. (1995b) Symbiosis between in vivo and in vitro NMR spectroscopy: the creatine, N-acetylaspartate, glutamate, and GABA content of epileptic human brain. Magn. Reson. Imag. 13, 1197-1211.
89. Petroff O. A. C., Spencer D., Alger J. R., and Prichard J. W. (1989) High-field proton magnetic resonance spectroscopy of human cerebrum obtained during surgery for epilepsy. Neurology 39, 1197-1202.
90. Pitkänen A., Ylinen A., and Matilainen R. (1993) Long-term antiepileptic efficacy of vigabatrin in drug-refractory epilepsy in mentally retarded patients: a 5 year follow-up study. Arch. Neurol. 50, 24-29.
91. Reikkinen P. J., Pitkänen A., Ylinen A., Sivenius J., and Halonen T. (1989a) Specificity of vigabatrin for the GABAergic system in human epilepsy. Epilepsia 30(Suppl. 3), S18-S22.
92. Reikkinen P. J., Ylinen A., Halonen T., Sivenius J., and Pitkänen A. (1989b) Cerebrospinal fluid GABA and seizure control with vigabatrin. Br. J. Clin. Pharmacy 27(Suppl. 1), 87S-94S.
93. Rimvall K. and Martin D. L. (1994) The level of GAD67 protein is highly sensitive to small increases in intraneuronal gamma-aminobutyric acid levels. J. Neurochem. 62, 1375-1381.
94. Roberts E. (1986) Failure of GABAergic inhibition: a key to local and global seizures. Adv. Neurol. 44, 319-341.
95. Roberts E. (1988) The establishment of GABA as a neurotransmitter, in GABA and Benzodiazepines Receptors, vol. 1. (Squires R. F., ed.) CRC Press, Boca Raton, FL., pp. 1-21.
96. Roberts E. and Frankel S. (1950) Gamma-aminobutyric acid in brain: its formation from glutamic acid. J. Biol. Chem. 187, 55-63.
97. 1H-double resonance difference spectroscopy of the rat brain in vivo. Proc. Natl. Acad. Sci. USA 81, 6330-6334.
98. 1H NMR measurements of glutamate in the human brain. Magn. Reson. Med. 25, 94-106.
99. 1H NMR measurements of GABA levels in human brain in vivo. Proc. Natl. Acad. Sci. USA 90, 5662-5666.
100. Schlechter P. J. (1989) Clinical pharmacology of vigabatrin. Br. J. Clin. Pharmacol 27(Suppl. 1), 19S-22S.
101. Schechter P. J. and Sjoerdsma A. (1990) Clinical relevance of measuring GABA concentrations in cerebrospinal fluid. Neurochem. Res. 15, 419-423.
102. Schechter P. J., Hanke N. F. J., Grove J., Huebert N., and Sjoerdsma A. (1984) Biochemical and clinical effects of gamma-vinyl-GABA in patients with epilepsy. Neurology 34, 182-186.
103. Schmid L., Bottlaender M., Brouillet E., Fuseau C., and Mazière M. (1996) Vigabatrin modulates benzodiazepine receptor activity in vivo: a positron emission tomography study in baboon. J. Pharmacol. Exptl. Ther. 276, 977-983.
104. Schousboe A., Larsson O. M., and Seiler N. (1986) Stereoselective uptake of the GABA-transaminase inhibitors gamma-vinyl GABA and gamma-acetylenic GABA into neurons and astrocytes. Neurochem. Res. 11, 1497-1505.
105. Schousboe A., Westergaard N., Sonnewald U., Petersen S. B., Yu A. C. H., and Hertz L. (1992) Regulatory role of astrocytes for neuronal biosynthesis and homeostasis of glutamate and GABA. Prog. Brain Res. 94, 199-211.
106. Schousboe A., Westergaard N., Sonnewald U., Petersen S. B., Huang R., Peng L., and Hertz L. (1993) Glutamate and glutamine metabolism and compartmentation in astrocytes. Dev. Neurosci. 15, 359-366.
107. Schousboe A. and Westergaard N. (1995) Transport of neuroactive amino acids in astrocytes, in Neuroglia (Kettenmann H. and Ransom B. R., eds.) Oxford University Press, New York, pp. 246-258.
108. Sellstrom A., Sjoberg L. B., and Hamberger A. (1975) Neuronal and glial systems for gamma-aminobutyric acid metabolism. J. Neurochem. 25, 393-398.
109. Shank R. P., Leo G. C., and Zielke H. R. (1993) Cerebral metabolic compartmentation as revealed by nuclear magnetic resonance analysis of D-[1-13C]glucose metabolism. J. Neurochem. 61, 315-323.
110. Sherwin A. L. and van Gelder N. M. (1986) Amino acid and catecholamine markers of metabolic abnormalities in human focal epilepsy. Adv. Neurol. 44, 1011-1032.
111. Sherwin A., Robitaille Y., Quesney F., Olivier A., Villemure J., Leblanc R., Feindel W., Andermann E, Gotman J., Andermann F., Ethier R., and Kish S. (1988) Excitatory aminoacids are elevated in human epileptic cerebral cortex. Neurology 38, 920-923.
112. 13C]NMR spectroscopy that glutamine from astrocytes is a precursor for GABA synthesis in neurons. Neurochem. Int. 22, 19-29.
113. Spencer S. S., Theodore W. H., and Berkovic S. F. (1995) Clinical applications: MRI, SPECT, and PET. Magn. Reson. Imag. 13, 1119-1124.
114. Spencer S. S. (1996) Long-term outcome after epilepsy surgery. Epilepsia 37, 807-813.
115. A receptors. Science 269, 977-981.
116. Storm-Mathisen J., Ottersen O. P., Fu-Long T., Gunderson V., Laake J. H., and Nordbo G. (1986) Metabolism and transport of amino acids studied by immunocytochemistry. Med. Biol. 64, 127-132.
117. Tasker J. G. and Dudek F. E. (1991) Electrophysiology of GABA-mediated synaptic transmission and possible roles in epilepsy. Neurochem. Res. 16, 251-262.
118. Taylor C. P. (1994) Emerging perspectives on the mechanism of action of gabapentin. Neurology 44(Suppl. 5), S10-S16.
119. Tunnicliff G. and Raess B. U. (1991) GABA neurotransmitter activity in human epileptogenic brain, in GABA Mechanisms in Epilepsy (Tunnicliff G. and Raess B. U., eds.) Wiley-Liss, New York, pp. 105-119.
120. van Donselaar C. A., Schimsheimer R., Geerts A. T., and Declerck A. C. (1992) Value of the electroencephalogram in adult patients with untreated first seizure. Arch. Neurol. 49, 231-237.
121. Vaughan T., and Pohost G. (1995) Proton nuclear magnetic resonance spectroscopic imaging of human temporal lobe epilepsy at 4.1 T. Ann. Neurol. 38, 396-404.
122. Ward H. K., Thanki C. M., and Bradford H. F. (1983) Glutamine and glucose as precursors of transmitter amino acids: ex vivo studies. J. Neurochem. 40, 855-860.
123. Wiesinger H. (1995) Glia-specific enzyme systems, in Neuroglia, (Kettenmann H. and Ransom B. R., eds.) Oxford University Press, New York, pp. 488-499.
124. A receptor/ion channel complex by intracellular GABA levels. Neurochem. Res. 16, 375-379.
125. Wood J. D. and Sidhu H. S. (1986) Uptake of gamma-aminobutyric acid by brain tissue preparations: a re-evaluation. J. Neurochem. 46, 739-744.
126. Wood J. H., Hare T. A., Glaeser B. S., Ballenger J. C., and Post R. M. (1979) Low cerebrospinal fluid gamma-aminobutyric acid content in seizure patients. Neurology 29, 1203-1208.